Navigation Links
TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
Date:8/31/2008

Landmark ARB trial investigated Micardis(R) (telmisartan) against placebo in reducing the composite endpoint of cardiovascular death, myocardial infarction, stroke and hospitalization for congestive heart failure in ACE inhibitor intolerant high-risk patients receiving current standard of care

RIDGEFIELD, Conn., Aug. 31 /PRNewswire/ -- The primary results of the TRANSCEND(TM)* trial demonstrated that treatment with MICARDIS(R) (telmisartan) 80mg in patients receiving current standard of care resulted in an 8% reduction in the composite endpoint of cardiovascular death, myocardial infarction, stroke and hospitalization for congestive heart failure. This reduction was not statistically significant (p=0.216; HR 0.92) compared to patients receiving placebo in addition to current standard of care.(1) Results of the main secondary endpoint of TRANSCEND as pre-specified in the statistical plan demonstrated that telmisartan significantly reduced the risk of cardiovascular death, myocardial infarction and stroke in high-risk cardiovascular patients by 13% compared with those patients already receiving current standard of care (p=0.048).(1) This risk reduction was achieved despite a high proportion of patients receiving proven therapies such as statins, anti-platelet agents or beta blockers. The main secondary endpoint of TRANSCEND mirrors the primary endpoint of the landmark HOPE trial.(2) A post-hoc analysis to adjust for multiplicity and overlap with primary endpoint showed a p-value of 0.068.(1) The results were presented today at the annual meeting of the European Society of Cardiology in Munich, Germany and published online in The Lancet.

In high-risk patients who cannot tolerate an angiotensin-converting enzyme (ACE) inhibitor, the TRANSCEND trial was designed to investigate potential cardiovascular risk reduction benefits using the second-generation angiotensin II receptor blocker (ARB) telmisartan. Telmisartan was compared to placebo on top of
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
(Date:8/29/2014)... -- According to the new research ... Reagent, Primer, Probe, Custom Oligos), End-User (Research, Pharmaceutical ... NGS, DNA, RNAi) - Global Forecast to 2019" ... is expected to reach $1,712.1 Million by 2019 ... CAGR of 9.8% from 2014 to 2019.. ...
(Date:8/29/2014)... , Aug. 29, 2014  Unilife Corporation ("Unilife" or ... today that it intends to release its financial results ... June 30, 2014 after market trading ends on Tuesday, ... a conference call for 4:30 p.m. U.S. EDT on ... 6:30 a.m. AEST), to review the Company,s financial results, commercial ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that ... Health Care Conference on Wednesday, March 9, 2011 at 11:00 ... Interested parties may access a live webcast of the presentation ... It is recommended that listeners log on 15 ...
... A new ad campaign warns Mississippi legislators that ... prescription drug benefits and undermine the ability of pharmacy ... Mississippi families and businesses, said the Pharmaceutical Care Management ... put the State Board of Pharmacy (instead of the ...
Cached Medicine Technology:Onyx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2New Ad Campaign: Secret Provision Raises Taxes on Prescription Drug Benefits, Creates 'Conflict of Interest' 2
(Date:9/2/2014)... Kicking blog MichaelHusted.com is featuring an interview ... role as a kicking coach, his kicking business, and on ... retired NFL kicker Michael Husted author of HustedKicking.com. , "Anthony ... one of the top pro free agent kickers out there,” ... at our 2014 Pro Camp and I was impressed with ...
(Date:9/2/2014)... 2014: The fact that mechanical heart valves increase risks ... from the ROPAC registry presented for the first time ... Professor Jolien W. Roos-Hesselink, co-chair with Professor Roger Hall ... 1.4% of pregnant women with a mechanical heart valve ... The Registry Of Pregnancy And Cardiac disease (ROPAC) is ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 “Harmonicas ... about a decade, primarily to help people with ... there are three developed systems,” says Dana Keller, ... substantively differ, the goals are much the same ... of some type of harmonica.” , The three ...
(Date:9/2/2014)... Fast hosting is a great choice for webmasters to ... hosting suppliers and announced that Arvixe, Bluehost and JustHost ... is hard to find a good fast hosting supplier. ... features, uptime, server speed and customer support. People can ... manager of Top10BestSEOHosting.com says. , Arvixe has a world-class ...
(Date:9/1/2014)... September 02, 2014 NAPW ... Healthcare, LLC as a 2014 Professional Woman of the ... for leadership in office management. As the largest, most-recognized ... virtually every industry and profession, the National Association of ... over 600,000 members and nearly 300 Local Chapters. , ...
Breaking Medicine News(10 mins):Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 2Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 3Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:Top10BestSEOHosting.com Recommends Fast Web Hosting Suppliers 2Health News:National Association of Professional Women Announces Victoria Smith, Office Manager at Apex Healthcare, LLC, a 2014 Professional Woman of the Year 2
... ... ... ... ...
... ... relied on chest x-rays, stress tests, CAT scans and MRIs," said Dr. Myron Licht, ... in better understanding heart failure and cardiopulmonary disease because it provides objective information--primal physiology ... ...
... ... Cleveland medical malpractice attorney nets settlement for widow. , ... Cleveland, OH (PRWEB) February 23, 2010 -- Medical negligence ... reports that he and his firm have obtained a substantial monetary settlement on behalf of ...
... ... ... ... ...
... ... ... ... ...
... , ... ... ... ...
Cached Medicine News:Health News:BUAV Exposes Shocking Role Played by Laos in the International Trade in Primates for Research 2Health News:BUAV Exposes Shocking Role Played by Laos in the International Trade in Primates for Research 3Health News:BUAV Exposes Shocking Role Played by Laos in the International Trade in Primates for Research 4Health News:BUAV Exposes Shocking Role Played by Laos in the International Trade in Primates for Research 5Health News:Apex Heart Care, First Arizona Clinic to Install Shape-HF; New Medical Device Measures Patient Physiology to Define Shortness of Breath 2Health News:Apex Heart Care, First Arizona Clinic to Install Shape-HF; New Medical Device Measures Patient Physiology to Define Shortness of Breath 3Health News:Cleveland Medical Malpractice Attorney Obtains Settlement in Wrongful Death Case 2Health News:Cleveland Medical Malpractice Attorney Obtains Settlement in Wrongful Death Case 3Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 2Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 3Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 4Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 5Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 6Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 7Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 2Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 3Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 4Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 5Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 6Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 7Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 2Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 3Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 4Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 5Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 6Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 7
... Our thawing systems are automated, easy to ... from the outside environment by flexible snap-seal ... bacterial or viral contamination of the water. ... the systems can also accommodate bags of ...
Conventional Digitally-Controlled Water Baths...
... a flexible, self-expanding nitinol design intended to ... biliary system, is now available from Cook ... and Drug Administration. Incorporating the features that ... successful around the world, the Zilver 518 ...
... double spot test is a rapid, ... antibodies to T. cruzi in human ... samples. This test is intended primarily ... reactive samples should be confirmed by ...
Medicine Products: